1
NCCN adds Mimrylo to polycythemia vera treatment guidelines
Likely
Resolves by Aug 28, 2027
Discussed by: Takeda, which called the approval a potential shift in the treatment paradigm; FDA reviewers who cited the drug's potential to reduce patient burden
Mimrylo launches with Phase 3 data showing a clear phlebotomy-reduction benefit. If community hematologists adopt it broadly, the National Comprehensive Cancer Network will likely add rusfertide to its myeloproliferative neoplasm guidelines. Takeda says the drug is already available to patients, removing a logistical barrier to adoption.
2
Major insurers impose barriers to Mimrylo coverage
Possible
Resolves by Aug 28, 2027
Discussed by: Reuters, which noted Takeda did not disclose a list price at launch
Takeda has not disclosed Mimrylo's list price, saying only that pricing would be fair to the value while ensuring access. For a chronic disease drug taken indefinitely, even a moderate annual price could lead insurers to require prior authorization or step therapy, forcing patients to try older treatments like hydroxyurea first. If that happens, the 48-hour availability matters less for patients whose insurers delay coverage.
3
Rusfertide expands into new iron disorder trials
Possible
Resolves by Aug 28, 2028
Discussed by: Iron metabolism researchers; Protagonist Therapeutics, which retains a US co-commercialization option
Mimrylo is the first approved drug built on hepcidin biology, but polycythemia vera is just one disease of iron regulation. Hereditary hemochromatosis, beta-thalassemia, and anemia of chronic disease all involve the same pathway. Protagonist, which can co-commercialize rusfertide in the US, has a financial stake in expanding the drug's use beyond PV.
4
Mimrylo sales miss Takeda's $1-2 billion peak projection
Uncertain
Resolves by Q2 2027
Discussed by: Reuters, which noted Takeda did not disclose a list price at launch
Takeda projects peak global sales of $1 billion to $2 billion for a drug treating roughly 90,000 Americans. No list price has been disclosed, and insurers have not yet set coverage policy. Protagonist's royalties, 14% to 29% of worldwide net sales, ride on the same number.
5
Mimrylo's broad label accelerates uptake beyond analyst projections
Possible
Resolves by May 31, 2027
Discussed by: Jefferies analyst Stephen Barker
Mimrylo's label does not require prior treatment with other drugs such as Jakafi, a broader scope than analysts expected. If community hematologists prescribe it early, sales could climb faster than consensus. Takeda projects peak sales of $1 billion to $2 billion.
6
Insurers weigh Mimrylo's $4,200-per-vial price in coverage decisions
Uncertain
Resolves by End of 2026
Discussed by: Reuters; Jefferies analyst Stephen Barker
At $4,200 per vial, a once-weekly Mimrylo regimen costs about $218,000 a year before discounts. Insurers and pharmacy benefit managers will set coverage policy in the coming months. The broad label could strengthen Takeda's negotiating position, but the price may still draw prior authorization or step therapy requirements.
